WikiJournal Preprints/Individualized clinical assessment and outcome interpretation in aesthetic botulinum neurotoxin type A treatment: a focused review

WikiJournal Preprints
Open access • Publication charge free • Public peer review

Submit

Authors

Reviewers

Editors

About

Journals

Journals

WikiJournal of Medicine

WikiJournal of Science

WikiJournal of Humanities

WikiJournal of PPB

WikiJournal Preprints

More resources

More resources

Open this menu as separate page

---

Articles in review
Editorial guidelines
Ethics statement
Bylaws
Indexing
Financials and reports
1-year/3-year plan
Proposed platform
Meeting minutes

---

Administrative board
Technical editors
Administrative officer
Calendar

---

Contact

WikiJournal is an emerging publishing house specialized in running open-access, free-to-publish, Wikipedia-integrated academic journals. <seo title=" Wikiversity Journal User Group, Wikiversity Press, WikiJournal, Free to publish, Open access, Open-access, Non-profit, online journal, Public peer review "/>

<meta name='citation_doi' value=>

This article is an unpublished pre-print undergoing public peer review organised by the WikiJournal of Medicine.

You can follow its progress through the peer review process at this tracking page.

First submitted: 18 Aug 2026

Reviewer comments

---

QID: Q141129555

---

Suggested (provisional) preprint citation format:
Saeed Ghezelbash. "Individualized clinical assessment and outcome interpretation in aesthetic botulinum neurotoxin type A treatment: a focused review". WikiJournal Preprints. Wikidata Q141129555. https://en.wikiversity.org/wiki/WikiJournal_Preprints/Individualized_clinical_assessment_and_outcome_interpretation_in_aesthetic_botulinum_neurotoxin_type_A_treatment:_a_focused_review. 

License: This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction, provided the original author and source are credited.

Editors:

Reviewers: (comments)

---

Article information

Author: Saeed Ghezelbash  

See author information ▼

Abstract

Botulinum neurotoxin type A (BoNT-A) is established for aesthetic reduction of selected dynamic facial lines, but treatment response cannot be inferred from a named facial region alone. Contemporary consensus literature increasingly emphasizes individualized assessment of facial anatomy, muscle activity, baseline asymmetry, treatment goals, product-specific characteristics, and post-treatment timing. This focused review synthesizes clinical-trial evidence, consensus recommendations, patient-journey frameworks, and recent anatomy-to-practice literature to organize these factors into a practical reasoning model. The central distinction is between the visible phenotype and its dominant driver: a line or contour may be predominantly dynamic, predominantly structural, or mixed. Assessment at rest and during animation helps determine whether neuromodulation is well matched to the problem and clarifies the degree of movement that should be preserved. Outcome interpretation should compare the observed result with the documented baseline, intended endpoint, expected time course, and contribution of static structural features before attributing dissatisfaction to pharmacologic non-response. Adjacent-muscle interactions and nonuniform motor-zone anatomy further limit one-size-fits-all approaches. The review proposes a seven-step assessment and reassessment framework intended to improve conceptual precision without prescribing universal injection points or interchangeable dosing rules.

Non-technical summary
Aesthetic botulinum toxin treatment works by reducing selected muscle activity, but similar-looking facial lines can have different causes and different treatment goals. This review explains why assessment should include the face both at rest and during movement, baseline asymmetry, interacting muscles, structural skin or volume changes, product-specific factors, and the timing of follow-up. It also provides a structured way to interpret an apparently weak, excessive, or asymmetric result before assuming that the drug itself failed.

Individualized clinical assessment and outcome interpretation in aesthetic botulinum neurotoxin type A treatment: a focused review

Introduction

Botulinum neurotoxin type A (BoNT-A) has a well-established role in aesthetic treatment of selected dynamic facial lines. Placebo-controlled clinical trials demonstrated efficacy for glabellar lines, and subsequent consensus statements expanded the clinical framework to include patient selection, facial analysis, anatomy, treatment goals, technique, and follow-up.

The existence of an effective pharmacologic intervention does not make the visible aesthetic concern a single-variable problem. A facial line, asymmetry, contour, or expression reflects interacting contributions from muscle activity, skin properties, volume, tissue position, skeletal support, previous procedures, baseline asymmetry, and patient-specific aesthetic goals. Contemporary consensus recommendations therefore increasingly favor individualized assessment rather than universal templates.

This focused review synthesizes selected high-relevance clinical-trial, consensus, patient-journey, and anatomy literature to provide a clinical reasoning framework for assessment before treatment and interpretation after treatment. It is not a systematic review, a dosing guideline, or a prescriptive injection atlas. Product labeling, approved indications, contraindications, formulation-specific units, and jurisdiction-specific regulatory requirements remain outside its scope.

Evidence approach

The review uses a focused narrative approach. Evidence was selected to represent complementary layers relevant to aesthetic BoNT-A reasoning: randomized efficacy evidence, foundational and contemporary consensus statements, patient-journey recommendations, and recent anatomy-to-practice synthesis. This approach is intended to clarify how different evidence types answer different questions rather than to estimate pooled treatment effects.

Randomized trials can establish efficacy and characterize adverse events for defined populations and protocols, but they do not determine an individualized plan for every facial phenotype. Consensus statements synthesize expert interpretation of anatomy, assessment, technique, and practice patterns, but should not be treated as equivalent to randomized evidence. Anatomy studies and reviews explain structural and motor-zone relationships but do not by themselves prescribe treatment. The reasoning model below therefore separates evidence about whether BoNT-A can work from evidence about how an individual presentation should be assessed.

From visible phenotype to dominant driver

A useful first distinction is between the visible phenotype and the mechanism that predominantly produces it. A named facial region is not itself a diagnosis of the dominant driver. The same visible line can reflect different proportions of dynamic muscle activity and static structural change.

A predominantly dynamic line becomes more apparent during animation because contraction changes the overlying soft-tissue configuration. A static component remains visible at rest and may reflect repeated folding, dermal remodeling, volume change, tissue quality, tissue position, or other structural factors. These categories form a continuum rather than a strict binary.

This distinction matters because BoNT-A primarily modifies neuromuscular transmission and therefore selected muscle activity. If muscle contraction is only one component of the visible finding, successful reduction of target movement may coexist with persistent resting change. A treatment can therefore produce the intended pharmacologic effect without producing complete disappearance of every visible line.

Assessment at rest and during animation

Consensus recommendations repeatedly emphasize assessment of the face in more than one state. Examination at rest identifies baseline position, asymmetry, static lines, tissue characteristics, and pre-existing contour differences. Animation reveals muscle recruitment patterns, relative strength, compensatory movement, and interactions among adjacent or opposing muscle groups.

The comparison between rest and animation is especially important when the clinical objective is selective neuromodulation rather than maximal movement reduction. Two patients with superficially similar dynamic lines can differ in baseline brow position, muscle strength, asymmetry, recruitment pattern, tissue support, previous treatment, and desired preservation of expression. Consequently, a region label does not encode a complete treatment plan.

A contemporary upper-face consensus also incorporated relevant anatomy, patient assessment and selection, individual variation, and complication-minimization strategies into product-specific recommendations, reinforcing the broader principle that individualized evaluation precedes technical execution.

Treatment goals and movement preservation

Aesthetic treatment success is not defined solely by the magnitude of movement reduction. The intended endpoint may include substantial reduction of a selected contraction, preservation of natural expression, improved symmetry, reduction of a specific dynamic line, or a negotiated balance among these objectives.

This makes goal definition part of the technical assessment rather than a separate administrative step. If clinician and patient use different implicit definitions of success, the same observed degree of muscle reduction can be interpreted differently. Explicit documentation of the desired endpoint provides a reference against which the post-treatment result can be judged.

The concept is consistent with broader patient-centered recommendations in facial aesthetics. A European consensus framework described screening, assessment, treatment, post-treatment evaluation, and follow-up as parts of a structured patient journey and emphasized goal clarification, medical-history review, risk-benefit discussion, documentation, and patient-reported outcomes.

Interacting muscles and balance

Facial movement emerges from interacting muscle groups rather than isolated named targets. Elevators, depressors, sphincters, synergists, and antagonists contribute to visible position and animation. Altering one component can change the apparent balance of the system even when the intended target responds as expected.

This has two implications. First, pretreatment asymmetry should be documented rather than inferred retrospectively. Second, a post-treatment asymmetry does not automatically establish that a new asymmetry was created; reduction of one movement pattern can unmask or amplify a pre-existing difference or an adjacent compensatory pattern. Interpretation requires comparison with baseline documentation and the original treatment objective.

The tailored-treatment literature explicitly emphasizes evaluation at rest and during animation, detailed understanding of facial muscular anatomy, and consideration of how opposing muscles interact. The broader global-consensus literature similarly supports individualized planning rather than fixed universal patterns.

Motor-zone anatomy and the limits of surface templates

Recent anatomy-to-practice work adds another layer to individualized reasoning. A 2026 narrative review of upper-face micro-innervation described nonuniform neuromuscular-junction distributions with muscle-specific patterns in the frontalis, corrugator supercilii, orbicularis oculi, procerus, and depressor supercilii. The author emphasized that these should be interpreted as probabilistic anatomical fields rather than deterministic injection maps.

This is conceptually important even without converting motor-zone maps into a prescriptive protocol. Surface landmarks provide only part of the relevant anatomical information. Depth, overlap, variation, and individual recruitment patterns can influence the relationship between a visible expression and the underlying neuromuscular target. Anatomy therefore complements dynamic assessment rather than replacing it.

Product-specific information versus general reasoning

A major source of conceptual error is treating formulation-specific information as if it were universally interchangeable. Different BoNT-A preparations have product-specific labeling, units, handling instructions, approved indications, and evidence bases. General clinical reasoning principles—such as defining the phenotype, assessing animation, documenting baseline asymmetry, and clarifying the treatment objective—can be discussed across products, but numerical dosing rules should not be generalized by assumption.

Consensus literature commonly combines general principles with formulation-specific recommendations. Readers should keep these evidence layers separate. A product-specific consensus can illustrate how individualized assessment is operationalized while still requiring that its dose and technique recommendations be interpreted within that formulation's evidence and regulatory context.

Interpreting an apparently inadequate response

An apparently weak result should be decomposed before being labeled pharmacologic non-response. At least five conceptually distinct explanations should be considered:

1. Timing of assessment. The observation may have been made before the expected effect was fully expressed or at a time point that is not comparable with the intended outcome assessment.
2. Residual structural component. Target movement may be reduced while a resting line or contour persists because it is partly structural.
3. Target-selection mismatch. The selected neuromuscular target may not have been the dominant driver of the visible concern.
4. Baseline or adjacent-muscle pattern. Residual or compensatory activity may dominate the post-treatment appearance.
5. Formulation, handling, placement, exposure, or true biological variability. These remain possible but should not be invoked before simpler phenotype, timing, and assessment explanations are considered.

The purpose of this decomposition is not to minimize true treatment failure. It is to prevent a broad patient-reported label such as “it did not work” from being treated as a single mechanistic diagnosis.

Interpreting excessive or asymmetric effects

The same reasoning applies when the result appears excessive or asymmetric. Clinically relevant categories include:

• excessive intended effect — more reduction of the intended muscle than required for the agreed endpoint;
• unintended local effect — clinically important influence on an adjacent structure;
• balance change — altered visibility of a pre-existing asymmetry or neighboring movement pattern after the target changes;
• structural-expectation mismatch — the pharmacologic effect occurs, but the overall appearance differs from the expected aesthetic outcome because nonmuscular contributors remain;
• systemic safety concern — symptoms beyond the expected local aesthetic effect require attention to product-specific warnings and appropriate medical evaluation.

Clinical trials and consensus publications document local adverse effects and emphasize anatomy, patient selection, technique, and follow-up as components of risk reduction.

A seven-step clinical reasoning framework

The evidence can be organized into a compact sequence that separates assessment from prescription:

1. Define the phenotype. Describe what is visible at rest and what changes during animation before naming a procedure.
2. Estimate the dominant driver. Determine whether the concern is predominantly muscular, predominantly structural, or mixed.
3. Document baseline balance. Record asymmetry, brow and eyelid position, neighboring recruitment, previous procedures, and other features that can affect interpretation.
4. Define the intended endpoint. Specify the desired degree of movement reduction, expression preservation, symmetry change, or other patient-centered goal.
5. Map interacting structures. Consider target muscles together with synergists, antagonists, and adjacent structures; use anatomy as a probabilistic guide rather than a universal template.
6. Keep product-specific rules product-specific. Do not assume numerical interchangeability among BoNT-A formulations; use the relevant labeling and evidence for the preparation being considered.
7. Reassess against baseline before assigning causality. Interpret apparent weak, excessive, or asymmetric outcomes in relation to timing, structural contributors, baseline documentation, and the original goal before concluding pharmacologic failure or technical error.

This sequence is intentionally not an injection protocol. Its purpose is to improve the quality of the questions asked before and after treatment.

Discussion

The literature reviewed here supports a shift from region-based thinking toward phenotype-based and goal-based reasoning. The evidence that BoNT-A can reduce selected dynamic lines is strong for established indications, but the path from efficacy evidence to individualized aesthetic outcome is mediated by anatomy, movement patterns, structural contributors, formulation-specific factors, expectations, and follow-up timing.

The dynamic-versus-structural distinction provides a useful organizing principle because it clarifies why a visible line may persist despite successful neuromodulation. The interacting-muscle model similarly clarifies why a change in one region can alter the appearance of another without implying that the target failed to respond. Recent motor-zone anatomy strengthens the argument that surface templates should be interpreted within a broader anatomical and functional assessment rather than treated as deterministic maps.

The proposed framework also highlights the importance of baseline documentation. Without a pretreatment record of rest position, animation, and asymmetry, post-treatment causal attribution becomes vulnerable to recall bias. Likewise, without an explicit intended endpoint, the term “successful treatment” can remain ambiguous even when objective movement change is apparent.

This review has limitations. It is focused and narrative rather than systematic, does not attempt meta-analysis, and deliberately avoids universal dosing recommendations. It also prioritizes conceptual integration of selected high-relevance evidence rather than exhaustive coverage of all formulations, indications, anatomical regions, or complication-management protocols. These boundaries are appropriate for the review's central question: how to reason about individualized assessment and outcome interpretation rather than how to reproduce a specific procedural technique.

Conclusion

Aesthetic BoNT-A treatment should not be reduced to a named facial region, a fixed template, or a single post-treatment observation. The clinically relevant sequence is to define the visible phenotype, identify the dominant dynamic and structural contributors, assess the face at rest and during animation, document baseline balance, clarify the desired endpoint, interpret anatomy in the context of interacting muscles, and reassess the result against baseline and timing before assigning causality.

This framework does not replace product-specific labeling, formal training, or clinical judgment. Its purpose is to make the reasoning that surrounds treatment more explicit. Better separation of pharmacologic effect, structural persistence, target-selection mismatch, balance change, and true non-response can improve both treatment planning and interpretation of outcomes.

Declarations

Author contribution

Saeed Ghezelbash conceived the review, synthesized the literature, developed the clinical reasoning framework, and prepared the manuscript.

Funding

No external funding was received for preparation of this manuscript.

Conflicts of interest

The author reports no financial conflict of interest related to this manuscript. The author practices aesthetic medicine.

Ethics

This focused review does not report new research involving human participants or animals and did not require institutional ethics approval.